Sarepta Therapeutics, Inc. (SRPT)

On our risk management desk, we are closely tracking the 34% year-over-year drop in total revenue down to $401.3 million for Q2 2026. Even though Sarepta managed to beat consensus earnings estimates with an adjusted EPS of 64 cents, the steep decline in Elevidys demand cannot be ignored. We are advising clients to maintain strict stop-losses because the core revenue erosion directly challenges the sustainability of their current valuation and multi-quarter outlook.

From a market sentiment perspective, Morgan Stanley and Citi maintain cautious stances despite the CEO transition. Bringing in Dr. Michael Severino to replace Doug Ingram is perceived as a positive structural move for long-term pipeline execution, but near-term sentiment remains weighed down by competitive pressures. The market is pricing in the reality that Sarepta's historical monopoly in the Duchenne muscular dystrophy exon-skipping segment is facing immediate challenges.

As a biotechnology quantitative analyst, I am noting the severe downside risks flagged by recent reports regarding Roche's Phase 3 study. Elevidys is Sarepta's primary one-shot gene therapy growth driver, and any clinical efficacy risk materializing from Roche's program creates an existential threat to the US franchise. The 3-month sentiment leaning heavily negative reflects this looming binary clinical overhang.

In our clinical immunology protocols, we are evaluating the competitive threat posed by Dyne Therapeutics' z-rostudirsen following the FDA's acceptance of their application. Citi's recent notes highlight that z-rostudirsen could differentiate itself from Sarepta's Exondys 51 on both efficacy and dosing frequency fronts. Clinicians are watching to see if these alternative profiles will disrupt standard-of-care adherence in our patient populations.

As a hedge fund portfolio manager, I view the Q2 2026 earnings beat as a temporary sentiment cushion rather than a structural turnaround. Total revenue fell 34% largely due to lower gene therapy demand and the absence of recurring regulatory milestone payments. While management narrowed product revenue outlooks and tightened expense guidance, the top-line contraction makes it hard to justify adding long exposure ahead of upcoming competitor data.